Trending Up0.0800 (2.0513%)
  • Bid / Lots
    2.9100/ 2
  • Ask / Lots
    6.3800/ 2
  • Open / Previous Close
    4.0000 / 3.9000
  • Day Range
    Low 3.7300
    High 4.0900
  • 52 Week Range
    Low 3.7300
    High 18.5150
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.9
09:32 ET25054
09:38 ET44603.81
09:48 ET30003.95
10:03 ET132833.75
10:06 ET10253.9
10:39 ET19003.87
10:44 ET1003.93
10:46 ET1003.94
10:48 ET1003.94
10:50 ET2003.94
10:55 ET4103.94
11:22 ET24003.98
12:09 ET12603.93
12:43 ET1004
12:48 ET1003.98
12:54 ET1004
12:59 ET1004
01:03 ET1004
01:30 ET1004
01:55 ET22504.01
01:57 ET16224.09
02:11 ET2004.07
02:13 ET3004.07
02:22 ET1004.07
02:40 ET3004.06
03:09 ET22004.09
03:12 ET1004.07
03:14 ET4884.05
03:34 ET1004.08
03:36 ET2004.03
03:43 ET1004.02
03:48 ET1004.05
03:56 ET11004.05
03:59 ET1003.98
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVOR
Vor Biopharma Inc
United StatesSBTX
Silverback Therapeutics Inc
United StatesAKUS
Akouos Inc
United StatesSVRA
Savara Inc
United StatesCTXR
Citius Pharmaceuticals Inc
United StatesLYRA
Lyra Therapeutics Inc
As of 2022-10-02

Company Information

Vor Biopharma Inc. is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. It offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.

Contact Information

100 Cambridgepark Drive, Suite 101CAMBRIDGE, MA, United States 02140


Independent Chairman of the Board
Matthew Patterson
President, Chief Executive Officer, Director
Robert Ang
Chief Financial Officer
Nathan Jorgensen
Chief Scientific Officer
Tirtha Chakraborty
Independent Director
Daniella Beckman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.